Lupin Gets USFDA Approval for Clobetasol Propionate Cream | CORPORATE ETHOS

Lupin Gets USFDA Approval for Clobetasol Propionate Cream

By: | February 1, 2018
lupin

Feb 1: Mumbai-based pharma major Lupin Ltd on Thursday announced that it has received final approval for its Clobetasol Propionate Cream USP, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of Fougera Pharmaceuticals Inc.’s Temovate Cream, 0.05%.

“Lupin’s Clobetasol Propionate Cream USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Cream, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses,” the company said.

According to IMS MAT October 2017 data, Clobetasol Propionate Cream USP, 0.05% had annual sales of approximately $135 million in the US.

Lupin shares were trading in red at Rs 862.90, down 2.35% from the previous closing of Rs 883.65, on BSE at 3.27 pm today.